EWTX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

34.550

Open

34.340

VWAP

33.67

Vol

677.14K

Mkt Cap

3.66B

Low

33.100

Amount

22.80M

EV/EBITDA(TTM)

--

Total Shares

107.59M

EV

3.17B

EV/OCF(TTM)

--

P/S(TTM)

--

Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.

Show More

Events Timeline

(ET)

2026-06-04

14:20:00

FDA Pledges to Prevent Political Interference in Meeting with Rare Disease Nonprofits

2026-06-01 (ET)

2026-06-01

10:10:00

Edgewise Therapeutics Stock Rises 17.5% to $40.15

2026-06-01

09:40:00

Edgewise Therapeutics Acquired by Servier for $1.55B

2026-06-01

08:40:00

Servier to Acquire Edgewise's Muscular Dystrophy Business for $2.65B

2026-06-01

08:40:00

Servier Acquires Edgewise Muscular Dystrophy Business for Up to $2.65B

2026-06-01

08:40:00

Edgewise Therapeutics Acquired by Servier for $2.65B

News

PRnewswire

06-03PRnewswire

Edgewise Grants Stock Options to New Employees

stocktwits

06-01stocktwits

Servier Acquires Edgewise's Muscular Dystrophy Operations

PRnewswire

06-01PRnewswire

Edgewise to Sell Muscle Disease Business for $1.55 Billion

Yahoo Finance

05-18Yahoo Finance

Biotech Fund Sells Erasca Stake After 700% Rally

Newsfilter

05-12Newsfilter

Achieve Life Sciences Appoints Three Senior Executives

stocktwits

05-05stocktwits

Cytokinetics' Heart Drug Trial Success Boosts Stock

9 Analyst Rating

Wall Street analysts forecast EWTX stock price to rise

8 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

16.00

Averages

38.14

High

51.00

Current: 0.000

Low

16.00

Averages

38.14

High

51.00

JPMorgan

Tessa Romero

Overweight

maintain

$45 -> $53

AI Analysis

2026-06-05

Reason

JPMorgan

Tessa Romero

Price Target

$45 -> $53

AI Analysis

2026-06-05

maintain

Overweight

Reason

JPMorgan analyst Tessa Romero raised the firm's price target on Edgewise Therapeutics to $53 from $45 and keeps an Overweight rating on the shares. Edgewise is up 46% year-to-date on growing enthusiasm around EDG-7500 and the hypertrophic cardiomyopathy market, but have not appreciated the recent Servier sale of Edgewise's sevasemten and the muscular dystrophy business in recent days, that included a "sizeable" upfront payment of $1.55B, the analyst tells investors in a research note. The firm says this will fully fund EDG-7500 development through potential approval and enable further expansion of Edgewis's cardiovascular pipeline.

H.C. Wainwright

Buy

maintain

$42 -> $45

2026-06-02

Reason

H.C. Wainwright

Price Target

$42 -> $45

2026-06-02

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Edgewise Therapeutics to $45 from $42 and keeps a Buy rating on the shares. The sale of sevasemten for up to $2.65B strengthens the company's balance sheet and enables it to focus exclusively on its cardiovascular pipeline, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EWTX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Edgewise Therapeutics Inc (EWTX.O) is 0.00, compared to its 5-year average forward P/E of -9.83. For a more detailed relative valuation and DCF analysis to assess Edgewise Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-9.83

Current PE

0.00

Overvalued PE

-4.56

Undervalued PE

-15.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-6.20

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-1.60

Undervalued EV/EBITDA

-10.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

19.74

Current PS

249.60

Overvalued PS

84.06

Undervalued PS

-44.59

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

good us stocks for weekly trading today

Intellectia · 591 candidates

Market Cap: >= 2.00BRegion: USRelative Vol: >= 1.20Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $0.00Is Optionable: TrueEma 5: >= 0Ema 20: >= 0Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Taylor Morrison Home Corp

5.47B

Epam Systems Inc

5.35B

MGM Resorts International

11.17B

Hewlett Packard Enterprise Co

57.11B

Grupo Cibest SA

16.27B

Science Applications International Corp

4.49B

give me best stocks to night trade tonight

Intellectia · 84 candidates

Market Cap: >= 500.00MVolume: >= 500,000Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20, PriceCrossAboveMA20Is Optionable: TrueMonthly Average Dollar Volume: >= 300,000News Driver: Positive

Ticker

Name

Market Cap$

EverQuote Inc

842.59M

Sterling Infrastructure Inc

24.73B

DigitalOcean Holdings Inc

15.94B

Viridian Therapeutics Inc

1.93B

Ballard Power Systems Inc

1.31B

Integra Lifesciences Holdings Corp

1.03B

stocks to buy right now for day trading

Intellectia · 416 candidates

Region: USPrice: >= $2.00Volume: >= 2,000,000Price Change Pct: >= $0.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA5, PriceAboveMA20Is Optionable: True

Ticker

Name

Market Cap$

Backblaze Inc

278.47M

Entravision Communications Corp

351.59M

Aura Biosciences Inc

536.07M

Cytokinetics Inc

8.21B

EverQuote Inc

516.80M

Strategy Inc

64.49B

day trading where do i go

Intellectia · 429 candidates

Price: $2.00 - $100.00Price Change Pct: >= $0.00Relative Vol: >= 1.50Beta: HighRiskMoving Average Relationship: PriceAboveMA5Week Price Change Pct: >= $0.00Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Cellectar Biosciences Inc

12.00M

Backblaze Inc

278.47M

Aura Biosciences Inc

536.07M

Cytokinetics Inc

8.21B

Viridian Therapeutics Inc

1.45B

EverQuote Inc

516.80M

Intellectia · 54 candidates

Market Cap: >= 2.00BAnalyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Hesai Group

3.73B

Riot Platforms Inc

5.75B

Spyre Therapeutics Inc

2.48B

Immunovant Inc

5.24B

Edgewise Therapeutics Inc

2.98B

Nuvalent Inc

7.99B

Whales Holding EWTX

Deerfield Management Company, L.P.

Driehaus Capital Management LLC

Paradigm Biocapital Advisors LP

Novo Holdings A/S

Soleus Capital Management, L.P.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Edgewise Therapeutics Inc (EWTX) stock price today?

The current price of EWTX is 33.345 USD — it has decreased -2.1

What is Edgewise Therapeutics Inc (EWTX)'s business?

Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.

What is the price predicton of EWTX Stock?

Wall Street analysts forecast EWTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EWTX is38.14 USD with a low forecast of 16.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Edgewise Therapeutics Inc (EWTX)'s revenue for the last quarter?

Edgewise Therapeutics Inc revenue for the last quarter amounts to -54.12M USD, increased 17.75

What is Edgewise Therapeutics Inc (EWTX)'s earnings per share (EPS) for the last quarter?

Edgewise Therapeutics Inc. EPS for the last quarter amounts to -42803000.00 USD, increased 12.91

How many employees does Edgewise Therapeutics Inc (EWTX). have?

Edgewise Therapeutics Inc (EWTX) has 146 emplpoyees as of June 11 2026.

What is Edgewise Therapeutics Inc (EWTX) market cap?

Today EWTX has the market capitalization of 3.66B USD.